668 related articles for article (PubMed ID: 15203749)
1. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
2. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. Subependymal giant cell astrocytoma: a clinicopathologic study with HMB45 and MIB-1 immunohistochemical analysis.
Gyure KA; Prayson RA
Mod Pathol; 1997 Apr; 10(4):313-7. PubMed ID: 9110292
[TBL] [Abstract][Full Text] [Related]
6. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
Prayson RA
Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
[TBL] [Abstract][Full Text] [Related]
7. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
8. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II alpha expression in esophageal squamous cell carcinoma.
Ohashi Y; Sasano H; Yamaki H; Shizawa S; Kikuchi A; Shineha R; Akaishi T; Satomi S; Nagura H
Anticancer Res; 1999; 19(3A):1873-80. PubMed ID: 10470130
[TBL] [Abstract][Full Text] [Related]
10. Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma.
Wang LF; Chai CY; Kuo WR; Tai CF; Lee KW; Ho KY
Am J Otolaryngol; 2006; 27(2):101-5. PubMed ID: 16500472
[TBL] [Abstract][Full Text] [Related]
11. Optic nerve gliomas: role of Ki-67 staining of tumour and margins in predicting long-term outcome.
Yeung SN; White VA; Nimmo M; Rootman J
Br J Ophthalmol; 2011 Aug; 95(8):1077-81. PubMed ID: 20921015
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 protein in gastric cancer: an immunohistochemical study with correlation to proliferative activity.
Ioachim E; Goussia A; Stefanou D; Agnantis NJ
Anticancer Res; 1997; 17(1A):513-7. PubMed ID: 9066704
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma.
Watanuki A; Ohwada S; Fukusato T; Makita F; Yamada T; Kikuchi A; Morishita Y
Anticancer Res; 2002; 22(2B):1113-9. PubMed ID: 12168909
[TBL] [Abstract][Full Text] [Related]
14. Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.
Buccoliero AM; Franchi A; Castiglione F; Gheri CF; Mussa F; Giordano F; Genitori L; Taddei GL
Neuropathology; 2009 Feb; 29(1):25-30. PubMed ID: 18564101
[TBL] [Abstract][Full Text] [Related]
15. The expression of proliferating cell nuclear antigen (PCNA) and p 53 protein correlate with prognosis of patients with oral squamous cell carcinoma.
Kurokawa H; Yamashita Y; Takeda S; Miura K; Murata T; Kajiyama M
Fukuoka Igaku Zasshi; 1999 Jan; 90(1):6-13. PubMed ID: 10087668
[TBL] [Abstract][Full Text] [Related]
16. PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma.
Lumachi F; Ermani M; Marino F; Iacobone M; Baldessin M; Cappuzzo G; Zanella S; Favia G
Anticancer Res; 2006; 26(2A):1305-8. PubMed ID: 16619538
[TBL] [Abstract][Full Text] [Related]
17. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis.
Coffin CM; Rulon J; Smith L; Bruggers C; White FV
Mod Pathol; 1997 Dec; 10(12):1175-87. PubMed ID: 9436961
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
Prayson RA; Mohan DS; Song P; Suh JH
Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
[TBL] [Abstract][Full Text] [Related]
19. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
Smith LM; Anderson JR; Coffin CM
Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
[TBL] [Abstract][Full Text] [Related]
20. MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma.
Ho DM; Hsu CY; Ting LT; Chiang H
Am J Clin Pathol; 2003 May; 119(5):715-22. PubMed ID: 12760291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
